- Home
- FORR vs CYBN Comparison
FORR vs CYBN Comparison
Compare FORR & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORR
- CYBN
- Stock Information
- Founded
- FORR 1983
- CYBN 2019
- Country
- FORR United States
- CYBN Canada
- Employees
- FORR N/A
- CYBN N/A
- Industry
- FORR Diversified Commercial Services
- CYBN Pharmaceuticals and Biotechnology
- Sector
- FORR Consumer Discretionary
- CYBN Health Care
- Exchange
- FORR Nasdaq
- CYBN Nasdaq
- Market Cap
- FORR 193.5M
- CYBN 176.0M
- IPO Year
- FORR 1996
- CYBN N/A
- Fundamental
- Price
- FORR $9.58
- CYBN $7.04
- Analyst Decision
- FORR
- CYBN Strong Buy
- Analyst Count
- FORR 0
- CYBN 3
- Target Price
- FORR N/A
- CYBN $85.00
- AVG Volume (30 Days)
- FORR 99.6K
- CYBN 370.5K
- Earning Date
- FORR 07-31-2025
- CYBN 08-13-2025
- Dividend Yield
- FORR N/A
- CYBN N/A
- EPS Growth
- FORR N/A
- CYBN N/A
- EPS
- FORR N/A
- CYBN N/A
- Revenue
- FORR $412,103,000.00
- CYBN N/A
- Revenue This Year
- FORR N/A
- CYBN N/A
- Revenue Next Year
- FORR $2.04
- CYBN N/A
- P/E Ratio
- FORR N/A
- CYBN N/A
- Revenue Growth
- FORR N/A
- CYBN N/A
- 52 Week Low
- FORR $8.50
- CYBN $4.81
- 52 Week High
- FORR $19.74
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- FORR 42.94
- CYBN 40.31
- Support Level
- FORR $9.68
- CYBN $7.22
- Resistance Level
- FORR $10.45
- CYBN $7.75
- Average True Range (ATR)
- FORR 0.56
- CYBN 0.35
- MACD
- FORR -0.07
- CYBN -0.04
- Stochastic Oscillator
- FORR 10.70
- CYBN 5.44
About FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.